<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03508765</url>
  </required_header>
  <id_info>
    <org_study_id>18-154</org_study_id>
    <nct_id>NCT03508765</nct_id>
  </id_info>
  <brief_title>Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation</brief_title>
  <official_title>Neurocognitive and Neuroimaging Outcomes in Older Patients With Multiple Myeloma Treated With Autologous Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to learn about possible changes in thinking (cognitive)
      abilities, such as memory skills, and in brain anatomy and function, in adults with multiple
      myeloma who are treated with high-dose chemotherapy followed by ASCT.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in neurocognitive functions in older participants with Multiple Myeloma following high-dose (HD) chemotherapy and autologous stem cell transplantation (ASCT) assessed by initial and follow-up neurocognitive evaluation</measure>
    <time_frame>up to 4 months following chemotherapy and ASCT</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in regional brain volume and functional connectivity when baseline and follow-up MRIs are compared.</measure>
    <time_frame>up to 4 months following chemotherapy and ASCT</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants diagnosed with multiple myeloma in complete, partial or very good partial remission per standard International Myeloma Working Group Criteria will complete neurocognitive tests and structural and functional rsfMRI (brain MRIs).</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Structural Image</intervention_name>
    <description>Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>Brain MRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Functional Image</intervention_name>
    <description>Patients will undergo structural and functional (rsfMRI) brain MRIs (total time= ~15 minutes) at enrollment (prior to HD-Chemo/ASCT) and approximately 3-4 months after ASCT.</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>rsfMRI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Digit Span subtest</intervention_name>
    <description>Evaluates auditory attention and working memory</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>WAIS-IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Brief Test of Attention</intervention_name>
    <description>Assesses selective auditory attention</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>BTA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Trail Making Test (Parts A &amp; B)</intervention_name>
    <description>Assesses visual scanning, graphomotor speed, and setshifting</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Auditory Consonant Trigrams Test</intervention_name>
    <description>Assesses attention and susceptibility to interference</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Controlled Oral Word Association Test</intervention_name>
    <description>A timed test of verbal fluency.</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>COWAT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Hopkins Verbal Learning Test-Revised</intervention_name>
    <description>The HVLT-R is a test of verbal learning and recall.</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>HVLT-R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>The Center for Epidemiological Study-Depression</intervention_name>
    <description>assesses perceived depression</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>CES-D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>The Functional Assessment of Chronic Illness Therapy-Fatigue Subscale, Version 4</intervention_name>
    <description>A 13-item questionnaire designed to assess symptoms and concerns specific to the QOL of patients with fatigue</description>
    <arm_group_label>rsfMRI + Neurocognitive Tests</arm_group_label>
    <other_name>FACIT-FS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with multiple myeloma and in complete, partial or very good partial
             remission at enrollment as per standard International Myeloma Working Group Criteria

          -  Scheduled to have high-dose chemotherapy and ASCT

          -  Age 60 - 75 years at study entry

          -  In the judgment of the consenting professional, fluent and able to communicate well
             enough in English to complete the study assessments and provide informed consent.

               -  Patients who report that English is not their primary language will be asked the
                  US Census English proficiency question &quot;How well do you speak English&quot; and the
                  answer &quot;very well&quot; will be required

        Exclusion Criteria:

          -  With signs and/or symptoms of central nervous system cancers (e.g., tumors,
             metastases, leptomeningial disease) as determined by their physician, medical records,
             or by a brain MRI, either at the time of enrollment or during the study period

          -  With current diagnosis of major Axis I psychiatric disorder (DSM-IV), major
             depression, bipolar disorder, or schizophrenia, as per medical records or patient
             report

          -  As per patient report or as confirmed by the medical record, if the patient is taking
             anti-depression or anti-anxiety medication, &lt; 2 months on these medications or a
             change in the prescribed dose in the past 2 months

          -  With history of a neurological disorder, neurodegenerative disease, or traumatic brain
             injury with loss of consciousness (&gt;60 minutes), as per medical records or patient
             report

          -  With a history of another cancer, except for non-melanoma skin cancer, as per medical
             records or patient report

          -  With current substance abuse and/or history of substance abuse, as per medical records
             or patient report

          -  With evidence of visual or auditory impairment that would preclude completion of the
             assessments, as per medical records or patient report

          -  With contraindications to MRI examinations as per standard screening guidelines used
             in the Department of Radiology (i.e., ferromagnetic material or implants, pacemakers
             or defibrillators, stents, claustrophobia)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise Correa, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise Correa, PhD</last_name>
    <phone>212-610-0491</phone>
    <email>corread@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Behroze Vachha, MD, PhD</last_name>
    <phone>212-639-2706</phone>
    <email>vachhab@mskcc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan - Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denise Correa, PhD</last_name>
      <phone>212-610-0491</phone>
      <email>corread@mskcc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mskcc.org</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2018</study_first_submitted>
  <study_first_submitted_qc>April 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2018</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ASCT</keyword>
  <keyword>Memorial Sloan Kettering Cancer Center</keyword>
  <keyword>18-154</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

